Caribou Biosciences is a technology company.
Caribou Biosciences has raised $161.0M across 3 funding rounds.
Caribou Biosciences has raised $161.0M in total across 3 funding rounds.
# Caribou Biosciences: A Clinical-Stage Biotech Pioneer
Caribou Biosciences is a clinical-stage biopharmaceutical company, not a technology company in the traditional sense—though it is deeply rooted in technology innovation. The company develops genome-edited allogeneic cell therapies for cancer and genetic diseases, leveraging proprietary CRISPR-based gene-editing technology as its core scientific foundation.[1][2]
Caribou focuses on transforming cancer treatment and genetic disease management through off-the-shelf cell therapies. The company develops engineered T-cell and NK-cell therapies designed to improve safety, efficacy, and persistence in patients with hematologic and solid tumor malignancies.[2] Beyond oncology, Caribou is advancing in vivo editing programs targeting monogenic disorders, including Duchenne muscular dystrophy and familial amyloidosis.[2]
The company's mission centers on addressing a critical limitation of existing cell therapies: the complexity and cost of manufacturing patient-specific treatments. By creating allogeneic (donor-derived) therapies that work across patient populations, Caribou aims to democratize access to advanced cell therapies while reducing manufacturing variability.[1]
Caribou was established in 2011 and co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.[2] The company emerged from groundbreaking research at UC Berkeley, where Doudna and Dr. Luciano Marraffini developed foundational CRISPR-Cas9 innovations.[1] Caribou holds licenses to foundational CRISPR intellectual property from the University of California, positioning it at the forefront of genome engineering.[2]
The company completed its initial public offering in July 2021, raising $202 million and marking its transition from private research to public clinical-stage development.[2] Since then, Caribou has focused on progressing its clinical pipeline and expanding manufacturing capabilities to support its growing roster of investigational therapies.[2]
Caribou operates at the intersection of two transformative biotech trends: CRISPR gene editing and allogeneic cell therapy. The timing is critical—cell therapy has moved from experimental to clinical reality, yet manufacturing remains a bottleneck. Caribou's approach addresses this by engineering universal donor cells rather than patient-specific treatments, potentially unlocking broader patient access and faster treatment timelines.
The company's work influences the broader ecosystem by demonstrating that CRISPR technology can move beyond theoretical applications into clinical practice. As regulatory pathways for gene-edited therapies mature, Caribou's clinical progress serves as a proof-of-concept for the entire field.[2]
Caribou stands at an inflection point. With its next earnings announcement scheduled for March 9, 2026, the company is advancing multiple clinical programs while navigating the capital-intensive nature of cell therapy development.[1] Wall Street analysts are cautiously optimistic, with 7 out of 9 analysts rating the stock as "Buy" and a median price target of $7.50.[5]
The company's future hinges on clinical trial success and manufacturing scale-up. If Caribou can demonstrate that its genome-edited allogeneic therapies match or exceed the efficacy of autologous approaches while reducing costs, it could reshape cancer treatment economics. The broader trend toward off-the-shelf cellular medicines—driven by manufacturing innovation and regulatory clarity—positions Caribou as a potential category leader in a market that could transform oncology over the next decade.
Caribou Biosciences has raised $161.0M in total across 3 funding rounds.
Caribou Biosciences's investors include 1435 Capital Management, 6th Man Ventures, Afore Capital, DFJ, E1 Ventures, Flucas Ventures, Founders Co-op, Heavybit, Invariantes Fund, Kleiner Perkins, KRM Interests LLC, LombardStreet Ventures.
Caribou Biosciences has raised $161.0M across 3 funding rounds. Most recently, it raised $120.0M Series C in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $120.0M Series C | 1435 Capital Management, 6th Man Ventures, Afore Capital, DFJ, E1 Ventures, Flucas Ventures, Founders Co-op, Heavybit, Invariantes Fund, Kleiner Perkins, KRM Interests LLC, LombardStreet Ventures, Maverick Capital, Menlo Ventures, Mouro Capital, Necessary Ventures, QED Investors, Robert Bosch Venture Capital, Starbridge Venture Capital, Sterling Equity, William Guo, XStarPartners, Adam Marchick, Andy Rubin, Dylan Taylor, hugo angelmar, Ravi Grover, Richard Cooperstein, Rob Meyerson, Sri Batchu, Sung ho Choi | |
| May 1, 2016 | $30.0M Series B | 6th Man Ventures, Amplify Partners, Anterra Capital, DFJ, Founders Co-op, Genoa Ventures, Heavybit, Kleiner Perkins, KRM Interests LLC, Maverick Capital, Menlo Ventures, Mouro Capital, Necessary Ventures, QED Investors, XStarPartners, Adam Marchick, Andy Rubin, hugo angelmar, Ravi Grover, Sri Batchu | |
| Mar 1, 2015 | $11.0M Series A | Amplify Partners, Genoa Ventures, Heavybit |